ADC Oncology Pair Trade Analysis

Strategic Assessment of Differentiated vs. Commoditized Players



Investment Research Report

February 2026

Sector:	Oncology / Biotechnology
Sub-sector:	Antibody-Drug Conjugates
Market Cap Focus:	Large Cap Pharma & Mid-Cap Biotech
Investment Horizon:	12–24 months

This report provides strategic analysis for investment research purposes. All information is derived from publicly available sources. This is not investment advice.

Contents

1 Executive Summary

1.1 Investment Thesis Overview

The antibody-drug conjugate (ADC) oncology market represents a compelling pair trade opportunity as the sector bifurcates between truly differentiated platforms and increasingly commoditized me-too assets. With global ADC revenues reaching approximately USD 12 billion in 2024 and projections exceeding USD 30 billion by 2033 [1, 2], the sector offers substantial alpha generation potential for investors who can correctly identify winners and losers in this rapidly evolving competitive landscape.

Core Thesis: Technology platform differentiation—specifically linker chemistry, payload mechanism, and drug-antibody ratio (DAR) optimization—creates durable competitive moats. Players with proprietary platforms targeting validated antigens with differentiated clinical profiles warrant long exposure, while me-too assets facing commoditization pressure from Chinese competitors warrant short consideration.

1.2 Key Findings

- **Market Structure:** The ADC market is consolidating around validated targets (HER2, TROP2) while simultaneously fragmenting into emerging targets (B7-H3, Claudin 18.2, FRα, Nectin-4). First-movers with differentiated technology retain pricing power.
- **Technology Differentiation:** Platform advantages derive from three pillars: (1) linker stability and cleavability, (2) payload potency and bystander effect capability, and (3) site-specific conjugation enabling optimal DAR. Enhertu's DXd platform (DAR 8, membrane-permeable payload) sets the benchmark.
- **Safety Signals:** Interstitial lung disease (ILD) remains the key class effect for topoisomerase I-based ADCs, with 10–15% incidence for T-DXd. Importantly, this is manageable with proper monitoring and does not negate clinical benefit [3].
- **Competitive Dynamics:** Chinese ADC players (Kelun-Biotech, RemeGen, Biocytogen) are rapidly building pipelines—China now accounts for 25% of traditional ADCs and 54% of bispecific ADCs globally [4]. This creates commoditization pressure for undifferentiated assets.

1.3 Investment Recommendations

Position	Company/Asset	Rationale
LONG	Daiichi Sankyo / AstraZeneca (Enhertu)	Best-in-class HER2 ADC, DXd platform, expanding indications, strong clinical data
LONG	Gilead (Trodelvy)	TROP2 pioneer, CNS penetration advantage, differentiated safety profile
WATCH	Pfizer-Seagen Portfolio	Strong assets (Padcev) but acquisition integration risk; pipeline depth uncertain
SHORT	Me-too TROP2 developers	Commoditization risk from Chinese competitors, limited differentiation
SHORT	Undifferentiated HER2 late-entrants	Market saturation in HER2 space, pricing pressure inevitable

2 Target Landscape Mapping

2.1 Current ADC Target Universe

The ADC oncology landscape is organized around validated molecular targets with established tumor expression patterns and clinical proof-of-concept. As of early 2026, 15 ADCs have received FDA approval targeting 16 distinct indications [5]. Figure 1 illustrates the expression patterns of key ADC targets across major cancer types.



Figure 1: **ADC Target Expression Landscape.** Heatmap showing relative target expression levels across major cancer types. Darker shading indicates higher expression. Targets include established (HER2, TROP2) and emerging (B7-H3, Claudin 18.2, FRα) antigens.

2.2 HER2: The Benchmark Target

HER2 (Human Epidermal Growth Factor Receptor 2) remains the most validated ADC target, with three approved agents generating substantial revenue:

- **Enhertu (trastuzumab deruxtecan, T-DXd):** USD 3.7 billion in 2024 revenue [1]. Approved for HER2+ breast cancer, HER2-low breast cancer, HER2+ gastric cancer, and HER2-mutant NSCLC. The paradigm-shifting DESTINY-Breast03 trial demonstrated superiority over T-DM1 with 28.8 months median PFS vs. 6.8 months [6].
- **Kadcyla (trastuzumab emtansine, T-DM1):** Roche's first-generation HER2 ADC, now facing competitive displacement from Enhertu in most settings.
- **HER2 Pipeline Saturation:** Multiple late-stage HER2 ADCs from Chinese developers risk commoditizing this space. The differentiation will come from payload innovation and indication expansion.

Investment Implication: HER2 is a "winner-take-most" market. Enhertu's clinical superiority and indication breadth create a durable moat. Late entrants face significant market access challenges.

2.3 TROP2: The Emerging Battleground

TROP2 (Trophoblast Cell Surface Antigen 2) represents the most competitive ADC space with three approved or near-approved agents:

- **Trodelvy (sacituzumab govitecan):** Gilead's TROP2 ADC achieved USD 1.3 billion in 2024 (+24% YoY). Key differentiator: superior CNS penetration with median OS exceeding 30 months in brain metastases patients [7].
- **Datroway (datopotamab deruxtecan):** AstraZeneca/Daiichi Sankyo's second TROP2 entry, FDA approved January 2025. Uses the same DXd payload platform as Enhertu.
- **Competitive Threats:** Kelun-Biotech's sacituzumab tirumotecan (licensed to MSD) enters Phase III in 2025 as potential "best-in-class" contender [4].

Real-world comparative data from ASCO 2025 revealed critical differentiation: T-DXd showed longer time-on-treatment than Trodelvy in HR+/HER2-negative disease (4.8 vs. 3.2 months, HR=0.801, $p<0.00001$), but Trodelvy demonstrated superior sequencing advantage in HR-/HER2-null tumors [7].

Investment Implication: TROP2 is becoming a commoditized target. Differentiation will depend on clinical positioning (HR status, brain metastases) and safety profiles rather than target alone.

2.4 Emerging Targets: Next-Generation Opportunities

2.4.1 B7-H3 (CD276)

B7-H3 represents the most promising emerging ADC target with pan-cancer expression validated across 156,791 samples spanning 50 cancer types [8]. Key pipeline assets:

- **MGC026 (MacroGenics):** Phase I in multiple solid tumors (NCT06242470), topoisomerase I payload
- Expression correlates with poor prognosis in prostate, ovarian cancers; potential for broad indication coverage

2.4.2 Claudin 18.2

Zolbetuximab (IMUGLANZI) approval in 2024 validates Claudin 18.2 as a gastric cancer target. ADC development ongoing with CMG901 in Phase II.

2.4.3 FRα (Folate Receptor Alpha)

Mirvetuximab soravtansine (ELAHERE) approved 2022 for ovarian cancer; expansion trials ongoing. Second-generation assets in development.

2.4.4 Nectin-4

Enfortumab vedotin (Padcev) dominates urothelial cancer; NSCLC expansion data expected 2025 (EV-302).

3 Differentiation Assessment: Linker/Payload Technology

3.1 ADC Technology Architecture

The therapeutic efficacy and competitive positioning of ADCs depends critically on three technology pillars: (1) antibody selection and engineering, (2) linker chemistry and stability, and (3) cytotoxic payload mechanism. Figure 2 illustrates the ADC mechanism of action.



Figure 2: **ADC Mechanism of Action.** Antibody-drug conjugates achieve tumor selectivity through: (1) target binding, (2) receptor-mediated internalization, (3) lysosomal processing, (4) payload release, and (5) bystander effect on neighboring cells.

3.2 Payload Technology Comparison

Figure 3 presents a comparative analysis of approved ADC technology platforms.



Figure 3: **ADC Technology Platform Comparison.** Key differentiators include payload class (topoisomerase I vs. tubulin inhibitors), drug-antibody ratio (DAR), linker type, and bystander effect capability.

3.3 Topoisomerase I Inhibitor Payloads: The New Standard

The topoisomerase I inhibitor class (DXd, SN-38) has emerged as the dominant payload platform for next-generation ADCs:

- **DXd (Deruxtecan):** Exatecan derivative with potent cytotoxicity. Features membrane permeability enabling robust bystander effect. Used in Enhertu (DAR $\sim$8) and Datroway.
- **SN-38:** Active metabolite of irinotecan. Used in Trodelvy (DAR $\sim$7.6) with pH-sensitive linker enabling CNS penetration.
- **Competitive Advantage:** Topoisomerase I inhibitors overcome resistance mechanisms affecting tubulin inhibitors (MMAE/DM1) in heavily pretreated patients.

3.4 Linker Technology and Drug-Antibody Ratio (DAR)

Linker design critically impacts pharmacokinetics, toxicity, and efficacy [9]:

Linker Type	Example ADC	Mechanism	Advantage
Cleavable (tetrapeptide)	Enhertu	Lysosomal protease	High DAR tolerance
pH-sensitive	Trodelvy	Acid hydrolysis	CNS penetration
vc-PAB (cleavable)	Adcetris	Protease cleavage	Established safety
Non-cleavable (thioether)	Kadcyla	Lysosomal degradation	Reduced systemic release

Site-Specific Conjugation: Next-generation ADCs increasingly employ engineered cysteine residues or non-canonical amino acids for homogeneous DAR distribution, reducing the DAR 0 (inactive) and DAR 8+ (unstable) species that plague conventional lysine conjugation [10].

3.5 Differentiation Score Card

ADC	Payload	DAR	Bystander	Indication	Score
Enhertu	DXd (Topo I)	8	Strong	Broad	**9/10**
Trodelvy	SN-38 (Topo I)	7.6	Strong	Focused	**8/10**
Padcev	MMAE (Tubulin)	4	Moderate	Expanding	**7/10**
Kadcyla	DM1 (Tubulin)	3.5	None	Narrow	**5/10**
Me-too TROP2	Various	Various	Variable	TBD	**3-4/10**

4 Safety Signal Analysis: The ILD Question

4.1 Interstitial Lung Disease Overview

Interstitial lung disease (ILD) and pneumonitis represent the most clinically significant adverse event associated with topoisomerase I-based ADCs, particularly trastuzumab deruxtecan (Enhertu). Understanding and contextualizing this safety signal is essential for accurate investment analysis.



Figure 4: **ILD Safety Management Algorithm.** Clinical management pathway for ADC-associated interstitial lung disease showing grade-based interventions, monitoring protocols, and retreatment considerations.

4.2 Incidence and Clinical Characteristics

Pooled analysis of nine T-DXd monotherapy trials (n=1,150 patients) reported 15.4% adjudicated ILD/pneumonitis incidence [11]:

Trial/Setting	Incidence	Grade $\geq$3	Fatal (Gr5)
DESTINY-Breast03	10.5%	0.5%	0%
DESTINY-Breast04	12.1%	0.8%	0.8%
Pooled 9 Trials	15.4%	1.5%	0.4%
BCBM Cohort	10%	Low	0%

Key Clinical Points:

- Median time to onset: 4.3 months (range 0.9–23.7 months)
- Resolution rate: 70.3% with appropriate management
- Most events are Grade 1–2 and manageable with treatment interruption

4.3 Management and Retreatment

Contemporary management protocols emphasize [3]:

1. **Baseline Assessment:** Pulmonary function tests (FVC, DLCO >70% predicted), high-resolution CT
2. **Monitoring:** Serial HRCT every 6 weeks (cycles 3, 5, etc.)
3. **Grade 1 Management:** Withhold T-DXd, monitor closely, consider corticosteroids
4. **Grade ≥2:** Corticosteroids mandatory, extended recovery period
5. **Grade ≥3:** Permanent discontinuation

Retreatment Data: Of 45 patients retreated after Grade 1 ILD recovery, 66.7% experienced no recurrence. Recurrent events (n=8) were all Grade ≤2 with median onset 64 days post-retreatment [11].

4.4 Investment Implications

- **Manageable Risk:** ILD is a real but manageable class effect. The clinical benefit demonstrated in pivotal trials significantly outweighs this risk in appropriate patient populations.
- **Competitive Consideration:** All topoisomerase I ADCs carry ILD risk. This is not a differentiating factor between Enhertu, Trodelvy, and next-generation assets.
- **Label Implications:** Robust monitoring protocols and patient education mitigate liability concerns. No major market access issues have emerged.
- **Comparative Safety:** FAERS data shows distinct safety profiles—T-DXd emphasizes musculoskeletal/infection events (33%/17%) while Trodelvy shows broader GI/cardiovascular effects (15%/14%) [12].

5 Emerging Targets and Pipeline Scan

5.1 Pipeline Evolution Timeline

Figure 5 illustrates the ADC approval and development timeline, highlighting the acceleration of novel target development.



Figure 5: **ADC Pipeline Evolution Timeline (2019–2027).** Key approval milestones and emerging target development windows. Color coding indicates target class: HER2 (blue), TROP2 (green), novel targets (purple).

5.2 Phase III and Late-Stage Pipeline

As of early 2026, over 40 ADCs are in Phase III development globally, with 25+ new Phase I entries during 2023–2025 [2]:

Target	ADC	Company	Stage	Indication
HER2	Enhertu	Daiichi/AZ	Approved	Multiple
HER2	Multiple	Chinese	Ph III	Breast, gastric
TROP2	Trodelvy	Gilead	Approved	Breast, urothelial
TROP2	Datroway	AZ/Daiichi	Approved	HR+/HER2- breast
TROP2	SKB264	Kelun/MSD	Ph III	Breast (2025)
Nectin-4	Padcev	Pfizer	Approved	Urothelial
Nectin-4	Padcev	Pfizer	Ph III	NSCLC (EV-302)
FRα	Elahere	ImmunoGen	Approved	Ovarian
CLDN18.2	CMG901	Keymed	Ph II	Gastric
B7-H3	MGC026	MacroGenics	Ph I	Solid tumors
CEACAM5	Tusamitamab	Sanofi	Ph III	NSCLC

Target	ADC	Company	Stage	Indication
HER3	Patritumab der.	Daiichi	Ph III	NSCLC
c-Met	Teliso-V	AbbVie	Ph III	NSCLC

5.3 Chinese ADC Development Surge

China has emerged as a global ADC development hub, creating both opportunities and competitive threats [4, 13]:

- **Pipeline Scale:** Biocytogen leads with 23 ADCs (17 discovery, 6 preclinical); ProfoundBio ranks 8th globally with 13 ADCs
- **Modality Innovation:** China accounts for 54% of bispecific ADCs and 38% of dual-payload ADCs globally
- **Deal Value:** USD 24 billion in ADC deal value increase (18% CAGR 2015–2025)
- **Operational Advantage:** Phase I trials completed in 9 months vs. 2 years in US; cost-efficient manufacturing

Key Chinese Players to Monitor:

1. **Kelun-Biotech:** SKB264 (TROP2) licensed to MSD; potential best-in-class
2. **RemeGen:** Innovative modalities in Yangtze Delta hub
3. **Biocytogen:** Largest Chinese ADC pipeline
4. **ProfoundBio:** Rina-S (FDA Fast Track, ovarian cancer)

6 Thesis Synthesis: Long vs. Short Candidates

6.1 Investment Framework

Figure 6 presents the strategic positioning framework for ADC oncology investments, mapping players across technology differentiation and market position dimensions.



Figure 6: **ADC Investment Positioning Framework.** Quadrant analysis mapping technology differentiation (x-axis) against market position/barriers to entry (y-axis). Green zone indicates long candidates; red zone indicates short candidates.

6.2 Long Thesis: Differentiated Players

6.2.1 LONG: Daiichi Sankyo (TYO: 4568) / AstraZeneca (LON: AZN)

Thesis: Best-in-class HER2 platform with proven expansion capability.

Key Drivers:

- **Enhertu Dominance:** USD 3.7B revenue (2024), market-leading efficacy data across 4+ indications
- **DXd Platform Value:** Same payload now powering Datroway (TROP2); platform optionality
- **Pipeline Depth:** HER3 ADC in Phase III, additional targets in development
- **Indication Expansion:** HER2-low/ultralow breast cancer dramatically expands addressable market
- **Clinical Moat:** DESTINY trial franchise establishes superiority across settings

Risks: ILD safety signal management, Chinese competition in HER2 space, AstraZeneca partnership economics.

Valuation Consideration: Premium justified by platform leadership and expansion optionality.

6.2.2 LONG: Gilead Sciences (NASDAQ: GILD)

Thesis: TROP2 pioneer with differentiated CNS penetration profile.

Key Drivers:

- **Trodelvy Performance:** USD 1.3B revenue (2024), +24% growth trajectory
- **CNS Advantage:** Median OS >30 months in brain metastases—critical differentiator
- **Sequencing Data:** Superior outcomes in HR-/HER2-null when used first
- **Safety Profile:** Distinct from T-DXd; may be preferred in certain patient populations
- **Underappreciated:** Market may undervalue TROP2 franchise within broader Gilead portfolio

Risks: Datroway competition, Kelun/MSD best-in-class threat, limited indication expansion vs. Enhertu.

6.3 Watch List: Transitional Assets

6.3.1 WATCH: Pfizer (NYSE: PFE) – Post-Seagen Integration

Thesis: Strong asset base but integration risk and unclear pipeline prioritization.

Considerations:

- **Padcev (Nectin-4):** Strong urothelial position; NSCLC expansion potential
- **Adcetris:** Lymphoma leader but older-generation MMAE platform
- **Integration Risk:** USD 43B Seagen acquisition requires flawless execution
- **Pipeline Clarity:** Need to demonstrate post-acquisition R&D productivity

Catalyst: EV-302 NSCLC data (2025) could rerate Padcev franchise.

6.4 Short Thesis: Commoditization Candidates

6.4.1 SHORT: Me-Too TROP2 Developers

Thesis: Target-only approach without technology differentiation faces pricing pressure.

Rationale:

- Multiple TROP2 ADCs in late development without clear clinical differentiation
- Chinese competition (Kelun/MSD) offers potential best-in-class at lower cost
- Market access increasingly difficult with three approved/near-approved agents
- Reimbursement pressure as payers demand differentiation evidence

Specific Considerations: Companies pursuing TROP2-only strategies without novel payload or indication approaches face challenging competitive dynamics.

6.4.2 SHORT: Undifferentiated HER2 Late-Entrants

Thesis: HER2 ADC market is effectively closed to undifferentiated competition.

Rationale:

- Enhertu's clinical superiority (PFS >4x vs. T-DM1) establishes insurmountable bar
- HER2-low/ultralow expansion by Enhertu captures previously unaddressed patients
- Late-stage HER2 ADCs from Chinese developers may face market access challenges
- Pricing pressure in China insufficient to offset Western market barriers

6.5 Risk Factors

1. **ILD Class Effect Escalation:** While currently manageable, any fatality cluster could impact the entire topoisomerase I ADC class.
2. **Regulatory Surprise:** Accelerated approval reversals or label restrictions could disrupt positioning.
3. **Chinese Outperformance:** If Kelun/MSD or other Chinese assets demonstrate clear best-in-class data, current differentiation thesis requires revision.
4. **Reimbursement Pressure:** Payer pushback on ADC pricing could compress margins across the sector.
5. **Novel Target Failure:** If emerging targets (B7-H3, etc.) fail to deliver clinical utility, pipeline value erodes.

7 Conclusion

7.1 Summary of Investment Thesis

The ADC oncology sector presents a compelling pair trade opportunity centered on technology differentiation as the key determinant of competitive sustainability. Our analysis identifies:

- **Long Candidates:** Daiichi Sankyo/AstraZeneca (Enhertu platform) and Gilead (Trodelvy CNS franchise) offer technology-protected positions with expanding clinical utility.
- **Short Candidates:** Undifferentiated TROP2 and HER2 developers face commoditization pressure from Chinese competition and market saturation.
- **Key Differentiators:** Payload mechanism (topoisomerase I supremacy), DAR optimization, linker technology, and clinical positioning (CNS penetration, HR/HER2 status stratification) separate winners from losers.
- **Safety Context:** ILD remains manageable with appropriate protocols and does not negate clinical benefit in validated indications.

7.2 Catalysts to Monitor

Timeline	Catalyst	Impact
H1 2026	Kelun/MSD SKB264 Phase III readout	TROP2 competitive dynamics
H2 2026	Pfizer EV-302 NSCLC expansion	Padcev rerating potential
2026	B7-H3 ADC early efficacy signals	Novel target validation
2026–2027	Chinese ADC ex-China approvals	Commoditization pressure test
Ongoing	ILD incidence in real-world setting	Class effect monitoring

7.3 Final Recommendation

PAIR TRADE RECOMMENDATION

LONG: Daiichi Sankyo / AstraZeneca (DXd platform leadership)

LONG: Gilead (Trodelvy CNS differentiation)

SHORT: Undifferentiated TROP2/HER2 developers facing commoditization

Investment Horizon: 12–24 months

References

[1] ADC Review. Antibody drug conjugates market expected to surge to us$30.42 billion by 2033. https://www.adcreview.com/, 2025. Enhertu USD 3.7B 2024 revenue.

[2] Roots Analysis. Antibody drug conjugates market report. https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/, 2025. Market projections USD 15.29B in 2025.

[3] Hope S. Rugo, Aditya Bardia, Frederik Marmé, et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan. *JCO Oncology Practice*, 19(6):460–469, 2023. doi: 10.1200/OP.22.00480. Comprehensive real-world management guidelines for T-DXd associated ILD.

[4] Beacon Intelligence. China's rise in adc development report. https://beacon-intelligence.com/market-reports/chinas-rise-in-adc-development-report/, 2025. China 25% traditional ADCs, 54% bispecific ADCs.

[5] Straits Research. Antibody drug conjugates market analysis. https://straitsresearch.com/report/antibody-drug-conjugates-market, 2025. 15 approved ADCs as of June 2025, USD 8B H1 2025 sales.

[6] Javier Cortés, Sung-Bae Kim, Wan-Ling Chung, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *New England Journal of Medicine*, 386:1143–1154, 2022. doi: 10.1056/NEJMoa2115022. DESTINY-Breast03 pivotal trial.

[7] Anonymous. Comparative real-world data analysis of trastuzumab deruxtecan and sacituzumab govitecan in her2-negative metastatic breast cancer. *PubMed Central*, 2025. ASCO 2025 presentation - T-DXd vs SG comparison.

[8] Christopher D. Miller et al. Pan-cancer interrogation of b7-h3 (cd276) as an immunotherapy target. *Clinical Cancer Research*, 2024. doi: 10.1158/1078-0432.CCR-23-4234. Analysis of 156,791 samples across 50 cancer types.

[9] Anonymous. Linker design for antibody-drug conjugates: A comprehensive overview. *ChemMedChem*, 2025. doi: 10.1002/cmdc.202500262. Reviews 17 approved ADCs with detailed linker analysis.

[10] WuXi XDC Team. A review of conjugation technologies for antibody-drug conjugates. *Antibody Therapeutics*, 2024. doi: 10.1093/abt/tlae015. Comparison of maleimide-cysteine vs site-specific conjugation.

[11] Daiichi Sankyo/AstraZeneca. Pooled analysis of trastuzumab deruxtecan (t-dxd) retreatment after recovery from grade 1 interstitial lung disease/pneumonitis (ild). *ESMO Breast Cancer Annual Congress*, 2024. 45 retreated patients, 67% no recurrence.

[12] Anonymous. Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and

sacituzumab govitecan-hziy with faers post-market surveillance data. *PubMed Central*, 2025. Safety profile comparison from FDA adverse event data.

[13] GlobalData. Chinese companies lead adc development pipeline. https://www.expresspharma.in/chinese-companies-lead-adc-development-pipeline-globaldata/, 2025. Biocytogen 23 ADCs, ProfoundBio 13 ADCs.

A Appendix: Approved ADC Summary

ADC	Target	Payload	Company	Indication
Enhertu	HER2	DXd	Daiichi/AZ	Breast, gastric, NSCLC
Kadcyla	HER2	DM1	Roche	Breast
Trodelvy	TROP2	SN-38	Gilead	Breast, urothelial
Datroway	TROP2	DXd	AZ/Daiichi	HR+/HER2- breast
Padcev	Nectin-4	MMAE	Pfizer	Urothelial
Adcetris	CD30	MMAE	Pfizer/Takeda	Lymphoma
Polivy	CD79b	MMAE	Roche	DLBCL
Blenrep*	BCMA	MMAF	GSK	Multiple myeloma
Elahere	FRα	DM4	ImmunoGen	Ovarian
Zynlonta	CD19	PBD	ADC Therapeutics	DLBCL
Tivdak	TF	MMAE	Pfizer	Cervical
Besponsa	CD22	Ozogamicin	Pfizer	ALL
Mylotarg	CD33	Ozogamicin	Pfizer	AML

*Withdrawn/re-approved status varies by region

B Appendix: Methodology Notes

This report synthesizes data from:

- Peer-reviewed clinical literature (NEJM, JCO, JAMA Network Open)
- Conference presentations (ASCO, ESMO, SABCS)
- Regulatory filings and FDA approval documents
- Market research reports (GlobalData, Beacon Intelligence, Straits Research)
- Company financial disclosures and earnings calls
- ClinicalTrials.gov registry data

All investment positioning reflects the author's analysis as of February 2026. This report is for informational purposes only and does not constitute investment advice.